U.S., April 10 -- ClinicalTrials.gov registry received information related to the study (NCT06920004) titled 'A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP' on March 26.
Brief Summary: The main purpose of this study is to compare empasiprubart and IVIg for treating people with CIDP. This study consists of a Part A where participants will either receive empasiprubart and a placebo resembling IVIg, or IVIg and a placebo resembling empasiprubart for 24 weeks (6 months). Following Part A, participants will enter Part B in which all participants will receive empasiprubart for 96 weeks (24 months).
Study Start Date: May, 2025
Study Type: INTERVENTIONAL
Condition:
Chronic Inflammatory Demyelinating Pol...